

# CMV & Me: Information for Transplant Patients

## What is cytomegalovirus (CMV)?

CMV is a common virus infecting people of all ages. It belongs to the family of herpes viruses. CMV does not usually cause serious problems in healthy people, but it is the most important serious infection affecting transplant patients.

CMV can be described as either an infection or a disease. CMV infection means that there is CMV reproducing; or making copies of the virus. CMV disease means that the virus has caused damage to an organ and is causing symptoms to occur.



## As a transplant recipient, am I at risk for CMV? How can I get CMV?

It is estimated that 50-80 percent of the population in the United States has been infected with CMV. Once CMV infects a person, it stays dormant in his or her body for life. Most people do not have signs or symptoms, but the virus can reactivate when the person's immune system is weakened.

Transplant patients may already have been exposed to CMV before their transplant. It is also possible for a transplant patient to receive a donor organ that has been infected with the virus. In rare situations, a transplant patient may become infected with CMV either as a result of contact with the virus within the community or after receiving blood that is CMV positive.

## Will I be tested for CMV before my transplant? Will my donor also be tested for CMV before the transplant occurs?

Transplant patients are screened for CMV both before and after the transplant occurs, and donors and donor organs are tested before transplantation. As part of their transplant evaluation, patients have blood samples drawn to determine if they have the virus.

## If I test positive for CMV, will I have to wait longer for my transplant?

CMV status will not delay your transplant. However, there may be more of a risk for potential organ transplant recipients if they are CMV negative. This is because they run the highest risk of receiving a primary infection either from receiving a CMV-positive organ or from the community while their immune system is at its weakest.


It is preferred that a CMV-negative patient receive a CMV-negative organ, but this is not usually possible. When CMV-negative patients receive a CMV positive organ, most transplant centers will note the patient as high-risk. Due to better antiviral medications and protocols, we lessen the risk of getting CMV if patients are treated with antiviral therapy for longer periods of time. When an organ becomes available, the best possible decision will be made for each potential recipient based on many factors, with CMV status as only one of those factors.



# Tips for Families & Caregivers

One of the most valuable things you can do as a caregiver is to offer support. You can help by ensuring your loved one does these things:

- Sees his or her doctor or transplant team regularly.
- Takes all of his or her medicine as directed by doctor or nurse.
- Seeks prompt medical attention for any signs or symptoms of CMV infection.
- Stays informed about his or her health.
- Asks doctor or transplant team any questions about his or her health or the health of the transplanted organ.



## Screening Donors for CMV

In some cases, living donors who have donated an organ to a loved one may feel guilty about the possibility of passing on CMV. Prior to the transplant, the doctor and transplant team will screen the live donors and determine the risk of transplanting a donated organ that is CMV-positive. With the help of a doctor or transplant team, this situation will be closely monitored.

## Helpful Resources

Listed below are sites you and your caregivers may find useful.

- [www.itns.org/index.php](http://www.itns.org/index.php)
- [www.cdc.gov/cmvi/index.html](http://www.cdc.gov/cmvi/index.html)
- [www.nlm.nih.gov/medlineplus/ency/article/000663.htm](http://www.nlm.nih.gov/medlineplus/ency/article/000663.htm)

NOTES: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

REFERENCES: This information is provided by Genentech, a member of the Roche Group. | Jointly developed by the International Transplant Nurses Society and Genentech, a member of the Roche Group.